Synergistic CDK Inhibition Systems
Legal Citation
Summary of the Inventive Concept
The present inventive concept integrates 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds with distinct technologies, such as AI, IoT, blockchain, and new materials, to create novel systems for CDK inhibition, enabling more effective and personalized cancer treatment.
Background and Problem Solved
The original patent disclosed CDK inhibitor compounds, but their efficacy and applicability were limited by the lack of integration with other technologies. The present inventive concept addresses this limitation by combining the patented compounds with innovative technologies, resulting in a more comprehensive and powerful system for CDK inhibition.
Detailed Description of the Inventive Concept
The inventive concept encompasses various systems and methods that synergistically combine the 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds with AI-based predictive models, blockchain-based decentralized data storage, graphene-based nanocarriers, IoT-enabled sensor arrays, and machine learning algorithms. These integrations enable real-time monitoring, personalized treatment, and optimized dosing regimens, ultimately leading to improved CDK inhibition efficacy and patient outcomes.
Novelty and Inventive Step
The new claims introduce novel synergistic combinations of the patented compounds with distinct technologies, which are not obvious from the original patent. The inventive step lies in the recognition of the potential for integration and the development of systems that leverage these combinations to achieve improved CDK inhibition.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different AI algorithms, blockchain architectures, or nanocarrier materials. Variations could involve the integration of additional technologies, such as CRISPR gene editing or quantum computing, to further enhance the CDK inhibition systems.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the cancer treatment market, particularly in personalized medicine and targeted therapies. The integration of innovative technologies with CDK inhibitor compounds is expected to attract interest from pharmaceutical companies, biotech startups, and research institutions.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical Chemistry and Computational Biology, with expertise in CDK inhibitor design, cancer therapeutics, and advanced drug delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in pharmaceutical chemistry, molecular biology, or biomedical engineering, possessing knowledge of drug design, computational modeling, and emerging medical technologies
Obviousness Rationale
A PHOSITA would recognize that integrating advanced computational and delivery technologies with existing CDK inhibitor compounds represents a natural progression in personalized medicine. The combination of known technologies with the source patent's compound follows established patterns of technological convergence in pharmaceutical research. The disclosed variations demonstrate predictable extensions of existing knowledge in drug delivery and treatment optimization.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,552 |
|---|---|
| Title | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors |
| Assignee(s) | CARRICK THERAPEUTICS LIMITED |